NO20010920L - Stabil hypoksi induserbar faktor-1<alfa> og anvendelsesmetoder - Google Patents

Stabil hypoksi induserbar faktor-1<alfa> og anvendelsesmetoder

Info

Publication number
NO20010920L
NO20010920L NO20010920A NO20010920A NO20010920L NO 20010920 L NO20010920 L NO 20010920L NO 20010920 A NO20010920 A NO 20010920A NO 20010920 A NO20010920 A NO 20010920A NO 20010920 L NO20010920 L NO 20010920L
Authority
NO
Norway
Prior art keywords
alpha
inducible factor
hypoxia
mutein
stable
Prior art date
Application number
NO20010920A
Other languages
English (en)
Norwegian (no)
Other versions
NO20010920D0 (no
Inventor
Gregg L Semenza
Original Assignee
Univ Johns Hopkins Med
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Johns Hopkins Med filed Critical Univ Johns Hopkins Med
Publication of NO20010920D0 publication Critical patent/NO20010920D0/no
Publication of NO20010920L publication Critical patent/NO20010920L/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4702—Regulators; Modulating activity
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Genetics & Genomics (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Dermatology (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Developing Agents For Electrophotography (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Breeding Of Plants And Reproduction By Means Of Culturing (AREA)
  • Manufacturing Of Steel Electrode Plates (AREA)
  • Compounds Of Unknown Constitution (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
NO20010920A 1998-08-25 2001-02-23 Stabil hypoksi induserbar faktor-1<alfa> og anvendelsesmetoder NO20010920L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US09/148,547 US6124131A (en) 1998-08-25 1998-08-25 Mutant hypoxia inducible factor-1 HIF-1
PCT/US1999/019416 WO2000010578A1 (fr) 1998-08-25 1999-08-25 Facteur-1 alpha stable inductible en hypoxie et procede d'utilisation

Publications (2)

Publication Number Publication Date
NO20010920D0 NO20010920D0 (no) 2001-02-23
NO20010920L true NO20010920L (no) 2001-04-23

Family

ID=22526230

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20010920A NO20010920L (no) 1998-08-25 2001-02-23 Stabil hypoksi induserbar faktor-1<alfa> og anvendelsesmetoder

Country Status (11)

Country Link
US (3) US6124131A (fr)
EP (1) EP1107768B1 (fr)
JP (1) JP2002523028A (fr)
AT (1) ATE344043T1 (fr)
AU (1) AU758627B2 (fr)
CA (1) CA2340328C (fr)
DE (1) DE69933877T2 (fr)
IL (2) IL141494A0 (fr)
NO (1) NO20010920L (fr)
NZ (1) NZ510002A (fr)
WO (1) WO2000010578A1 (fr)

Families Citing this family (43)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2001525173A (ja) * 1997-12-04 2001-12-11 ジェンザイム・コーポレーション 遺伝子発現を誘導するための組成物および方法
US6124131A (en) * 1998-08-25 2000-09-26 The Johns Hopkins University School Of Medicine Mutant hypoxia inducible factor-1 HIF-1
FR2801319A1 (fr) * 1999-11-18 2001-05-25 Inst Nat Sante Rech Med Construction d'acide nucleique porteuse d'un systeme regulant l'expression d'un gene
WO2002012326A2 (fr) * 2000-08-07 2002-02-14 Angiogenetics Sweden Ab Mecanisme de regulation conditionnelle du facteur-1 inductible par l'hypoxie au moyen de la proteine suppresseur de tumeur de von hippel-lindau
US20040101825A1 (en) * 2001-09-26 2004-05-27 Van Meir Erwin G. Viruses targeted to hypoxic cells and tissues
US7285414B2 (en) * 2000-09-26 2007-10-23 Emory University Viruses targeted to hypoxic cells and tissues
US6849718B2 (en) 2001-03-20 2005-02-01 Dana Farber Cancer Institute, Inc. Muteins of hypoxia inducible factor alpha and methods of use thereof
US6660737B2 (en) 2001-05-04 2003-12-09 The Procter & Gamble Company Medicinal uses of hydrazones
US6878729B2 (en) 2001-05-04 2005-04-12 The Procter & Gamble Company Medicinal uses of dihydropyrazoles
US7247620B2 (en) 2001-05-09 2007-07-24 Anges Mg, Inc. Method of treating skin wounds with vectors encoding hepatocyte growth factor
AU2002302252A1 (en) * 2001-05-23 2002-12-03 Angiogene Inc. Hypoxia inducible factors and uses thereof for inducing angiogenesis and improving muscular functions
US6838430B2 (en) 2001-09-28 2005-01-04 The Regents Of The University Of California Use of HIF-1a variants to accelerate wound healing
US20030093147A1 (en) * 2001-11-13 2003-05-15 Ogle Matthew F. Medical devices that stimulate growth factor production
CN102526045A (zh) * 2001-12-06 2012-07-04 法布罗根股份有限公司 提高内源性红细胞生成素(epo)的方法
US7053046B2 (en) * 2001-12-21 2006-05-30 Mcgrath Kevin Peptide activators of VEGF
US20030199464A1 (en) * 2002-04-23 2003-10-23 Silviu Itescu Regeneration of endogenous myocardial tissue by induction of neovascularization
US7618940B2 (en) 2002-12-06 2009-11-17 Fibrogen, Inc. Fat regulation
RU2346688C2 (ru) * 2002-12-06 2009-02-20 Фиброген, Инк. Регулирование содержания жира
US8124582B2 (en) 2002-12-06 2012-02-28 Fibrogen, Inc. Treatment of diabetes
CN101518535A (zh) * 2002-12-06 2009-09-02 法布罗根股份有限公司 脂肪调节
US8614204B2 (en) 2003-06-06 2013-12-24 Fibrogen, Inc. Enhanced erythropoiesis and iron metabolism
JP2007509611A (ja) * 2003-10-17 2007-04-19 アクティス バイオロジクス， インコーポレイテッド 癌を処置するためのｍｓｐ３６のレンチウイルスベクター送達
EP1686979A4 (fr) * 2003-11-07 2010-03-03 Jackson H M Found Military Med Activation d'expression genique pouvant etre induite par hypoxie
JP2007512369A (ja) * 2003-11-26 2007-05-17 エンテロス・インコーポレーテッド 低酸素誘導因子１αアンタゴニストを用いる慢性関節リウマチの処置
US20050137568A1 (en) * 2003-12-17 2005-06-23 Jones Donald K. Activatable bioactive implantable medical device and method of use
US7294123B2 (en) * 2003-12-17 2007-11-13 Corris Neurovascular, Inc. Activatable bioactive vascular occlusive device and method of use
JP2007516727A (ja) * 2003-12-31 2007-06-28 アクティス バイオロジクス， インコーポレイテッド 癌を処置するためのネイティブｉｇｆｂｐ−３および変異型ｉｇｆｂｐ−３のレンチウイルスベクター送達
US7247159B2 (en) * 2004-04-08 2007-07-24 Cordis Neurovascular, Inc. Activatable bioactive vascular occlusive device
WO2006009843A2 (fr) * 2004-06-18 2006-01-26 The Johns Hopkins University Regulation negative du facteur 1 induisant l'hypoxie par os-9
CN1319525C (zh) * 2004-09-16 2007-06-06 北京圣医耀科技发展有限责任公司 紫杉醇－海藻酸钠微球血管栓塞剂及其制备
WO2006130320A2 (fr) * 2005-05-11 2006-12-07 University Of Florida Research Foundation, Inc. Reparation du systeme vasculaire de la moelle osseuse
ATE470439T1 (de) 2005-06-15 2010-06-15 Fibrogen Inc Verwendung von hif 1alfa modulatoren zur behandlung von krebs
GB0520176D0 (en) * 2005-10-04 2005-11-09 Imp College Innovations Ltd Use
US20090215687A1 (en) * 2005-10-21 2009-08-27 Cornell Research Foundation, Inc. Compounds for Enhancing Hypoxia Inducible Factor Activity and Methods of Use
KR100959538B1 (ko) * 2006-03-30 2010-05-27 엘지전자 주식회사 비디오 신호를 디코딩/인코딩하기 위한 방법 및 장치
US7759306B2 (en) * 2006-05-16 2010-07-20 Simoni Jan S Methods of treating acute blood loss
CN102796741A (zh) 2006-07-31 2012-11-28 脉管生物生长有限公司 多肽和其编码多核苷酸及它们在治疗缺血相关医学病症中的应用
US20080081354A1 (en) * 2006-10-02 2008-04-03 Cardiac Pacemakers, Inc. Devices, vectors and methods for inducible ischemia cardioprotection
DK2066791T3 (da) 2006-10-03 2012-10-15 Genzyme Corp Genterapi for amyotrofisk lateralsklerose og andre rygmarvssygdomme
KR100992526B1 (ko) * 2007-11-21 2010-11-05 한국과학기술연구원 이황화결합을 이용한 내열성의 알파-1-안티트립신 뮤테인및 그의 제조방법
US9446031B2 (en) 2012-01-18 2016-09-20 National University Of Singapore Compositions and methods for neovascularization
WO2017027810A2 (fr) * 2015-08-12 2017-02-16 The General Hospital Corporation Compositions et méthodes qui favorisent l'hypoxie ou la réponse hypoxique pour le traitement et la prévention d'un dysfonctionnement mitochondrial et de troubles du stress oxydatif
WO2020146758A1 (fr) 2019-01-10 2020-07-16 The General Hospital Corporation Méthodes de traitement de dysfonctionnements ou de maladies associés aux mitochondries

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5882914A (en) 1995-06-06 1999-03-16 The Johns Hopkins University School Of Medicine Nucleic acids encoding the hypoxia inducible factor-1
US6099832A (en) * 1997-05-28 2000-08-08 Genzyme Corporation Transplants for myocardial scars
JP2001525173A (ja) * 1997-12-04 2001-12-11 ジェンザイム・コーポレーション 遺伝子発現を誘導するための組成物および方法
US6124131A (en) * 1998-08-25 2000-09-26 The Johns Hopkins University School Of Medicine Mutant hypoxia inducible factor-1 HIF-1

Also Published As

Publication number Publication date
EP1107768A4 (fr) 2004-12-29
CA2340328A1 (fr) 2000-03-02
ATE344043T1 (de) 2006-11-15
US6562799B1 (en) 2003-05-13
WO2000010578A1 (fr) 2000-03-02
CA2340328C (fr) 2011-06-21
EP1107768B1 (fr) 2006-11-02
US20030176349A1 (en) 2003-09-18
AU758627B2 (en) 2003-03-27
JP2002523028A (ja) 2002-07-30
IL141494A (en) 2009-05-04
AU5691499A (en) 2000-03-14
US6124131A (en) 2000-09-26
DE69933877T2 (de) 2007-06-21
NO20010920D0 (no) 2001-02-23
EP1107768A1 (fr) 2001-06-20
DE69933877D1 (de) 2006-12-14
IL141494A0 (en) 2002-03-10
NZ510002A (en) 2003-11-28

Similar Documents

Publication Publication Date Title
NO20010920D0 (no) Stabil hypoksi induserbar faktor-1&lt;alfa&gt; og anvendelsesmetoder
ATE31625T1 (de) Pharmazeutisches mittel zur behandlung des diabetes mellitus.
Ingimarsson et al. Side effects of long-term treatment with human leukocyte interferon
KR950700333A (ko) 개량된 알파 인터페론 조성물 및 인간 말초혈 백혈구로부터의 제조 방법(improved alpha interferon composition and method for its production from human peripheral blood leukocytes)
CO4970691A1 (es) Terapia en combinacion para erradicar vhc-arn detectable en pacientes que padecen infeccion de hepatitis c cronica
NL300382I1 (nl) Treatment of pompe&#39;s disease
LV10180A (lv) Farmaceitiska kompozicija
DK0815860T3 (da) Terfenadincarboxylat og behandlingen af allergiske lidelser
FI103180B1 (fi) Flurbiprofeenia sisältävien lääkkeiden valmistus kipujen ja/tai tulehdusten torjumiseksi eläimissä ja ihmisissä
PT950057E (pt) Enantiomeros de 3-piridilo e sua utilizacao como analgesicos
PT639979E (pt) Ligando para o receptor c-kit e metodos para a sua utilizacao
DE3588023D1 (de) Mittel zur Behandlung von Herzerkrankungen.
DE68926679D1 (de) Physiologisch aktives polypeptid, rekombinantes plasmid, rekombinante mikrobielle zellen, medizinisches präparat sowie verfahren zur gewinnung des gereinigten polypeptids
WO2003034996B1 (fr) Utilisation de leptine pour traiter la lipoatrophie humaine et procede pour determiner une predisposition a ce traitement
ATE187642T1 (de) Verwendund von norastemizol zur behandlung der allergischen rhinitis
FI885807L (fi) Puhdistetun, biologisesti aktiivisen, bakteerien avulla tuotetun rekombinanttisen ihmis- CSF-1:n tuottaminen
DK0817646T3 (da) Fremgangsmåder til behandling af inflammation og præparater derfor
BR9007115A (pt) Novo trombolitico
DE69111974D1 (de) Verwendung von Lithium zur Behandlung oder Prophylaxe von Molluscum contagiusum.
ATE80039T1 (de) Pharmazeutische zusammensetzung, enthaltend 2&#39;,3&#39;-dideoxycytidin-2&#39;-en(2&#39;,3&#39;-dideoxy-2&#39;,3&#39;didehydrocytidin) zur behandlung von mit retrovirus infizierten patienten.
Silverman et al. Activation of herpes simplex following dermabrasion: report of a patient successfully treated with intravenous acyclovir and brief review of the literature
IT8224624A0 (it) Sale metilglucamminico del flurbiprofen dotato di attivita&#39;terapeutica e procedimento per lasua preparazione.
WO1990004977A3 (fr) Traitement de condylomes genitaux a l&#39;aide d&#39;une combinaison d&#39;azote liquide et d&#39;interferon alpha humain d&#39;adn de recombinaison
ATE428438T1 (de) Tcf-ii enthaltende medizinische zusammensetzung
KR100488038B1 (ko) 기관 보호 활성을 지닌 신규한 신체 보호 화합물 펩티드염, 이의 제조 방법 및 치료에서의 이의 용도

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application